# Microbot Medical Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Microbot Medical Inc.). ## Overview Microbot Medical Inc. is a development-stage medical device company focused on robotic-assisted endovascular surgery. Its core effort is the LIBERTY® Endovascular Robotic Surgical System, a platform intended to help physicians perform vascular procedures with remote robotic control and improved precision. ## Products & services • LIBERTY® Endovascular Robotic Surgical System • Robotic-assisted endovascular procedure platform • Prototype development and engineering services • Regulatory and commercialization support for device launch - **Robotic endovascular system** (0%) — The LIBERTY® platform and related robotic hardware/software for minimally invasive vascular procedures. - **Product development and prototyping** (60%) — Engineering, prototype materials, and research studies used to advance the device pipeline. - **Regulatory and commercialization preparation** (25%) — Activities supporting clinical, regulatory, and market launch readiness for the system. - **Intellectual property and portfolio maintenance** (15%) — Patent portfolio work and related development-stage support costs tied to the platform. - LIBERTY® Endovascular Robotic Surgical System - Endovascular robotic navigation and control platform - Prototype design, testing, and engineering development - Regulatory and commercialization readiness activities ## Customers Microbot is not yet generating revenue, so it does not have a broad commercial customer base today. Its eventual buyers are expected to be hospitals, interventional physicians, and healthcare systems that perform endovascular procedures and want robotic assistance for precision, workflow, and operator safety. The company also depends on investors and grant providers to fund development until commercialization scales. - **Hospitals and health systems** (primary) — Future purchasers of the LIBERTY system for vascular procedure rooms and interventional suites. - **Interventional physicians** (primary) — Clinical users who would adopt the platform to improve control, precision, and ergonomics. - **Government grant agencies** (secondary) — Public funding sources such as the Israeli Innovation Authority that support R&D. - **Equity and debt investors** (primary) — Capital providers that fund operations until product commercialization generates revenue. - Hospitals and health systems planning endovascular robotics adoption - Interventional physicians seeking more precise remote procedure control - Vascular procedure centers evaluating minimally invasive workflow tools - Government grant agencies funding medtech development - Capital providers financing development and commercialization ## Geography Microbot is headquartered in the United States but has meaningful operational exposure to Israel through its office, subcontractors, vendors, and regulatory support activities. The company specifically notes that military operations and flight disruptions in Israel can affect importing materials, shipping devices, and supporting clinical and regulatory milestones. No country-level revenue is disclosed because the company has not yet generated operating revenue. - United States headquarters and public-company base - Israel-based office and supply chain support activities - Israeli subcontractors and vendors support development work - Cross-border shipping and import logistics matter for device buildout - No operating revenue disclosed yet, so market mix is not available ## Strategy Microbot’s near-term strategy is to fund and complete commercialization of the LIBERTY® Endovascular Robotic Surgical System while continuing R&D on future versions and applications. The company is also prioritizing capital raising through equity-linked financings and ATM usage to support working capital, public-company costs, and development milestones. - **Commercialize LIBERTY® Endovascular Robotic Surgical System** (short-term) — The company needs product launch success to transition from development-stage funding to operating revenue. - **Raise additional capital as needed** (short-term) — Microbot currently relies on external financing to fund operations and development. - **Develop future versions and applications** (medium-term) — Pipeline expansion can extend the platform beyond the initial product and broaden market opportunity. - Advance commercialization of the LIBERTY® system - Use equity and equity-linked financing to fund operations - Expand commercialization capabilities ahead of launch - Continue R&D for future versions and applications - Maintain liquidity while managing public-company overhead ## Risks Microbot remains a pre-revenue company, so its business model depends on successful product development, regulatory progress, and repeated access to capital. The company also faces operational exposure in Israel, where military disruptions can affect suppliers, logistics, and clinical/regulatory work, while future dilution and debt covenants could constrain shareholders and operations. - **Financing dependence and dilution** [high] — The company has not generated revenue and must fund commercialization through equity, debt, and option exercises. - **Israel geopolitical and logistics disruption** [high] — Israeli subcontractors, vendors, flights, and import/shipping channels can be disrupted by military activity. - **Commercialization execution risk** [high] — The company must convert a development-stage product into a marketable system with regulatory and adoption milestones. - **Ongoing losses and cash burn** [high] — R&D, public-company, and commercialization costs continue before revenue generation begins. - No operating revenue yet, so the company depends on financing - Equity raises can dilute existing shareholders - Debt financing could add covenants and repayment obligations - Israel-based operations face supply chain and logistics disruption risk - Commercialization and regulatory milestones may slip if development slows ## Accounting The company’s reporting is dominated by development-stage accounting, with no operating revenue and recurring losses that limit tax benefit recognition. Investors should watch fair value measurements, grant-related offsets, and the accounting for equity-linked financings, because these items can materially affect cash flow presentation, expense recognition, and dilution analysis. - **Research and development expense recognition** — Affects operating loss and cash burn visibility - **Government grants and royalty obligations** — Affects net R&D expense and future gross margin economics - **Fair value of financial instruments** — Can affect earnings and balance sheet values - **Equity and preferred investment option exercises** — Affects dilution, cash resources, and per-share metrics - **Income tax valuation on net operating losses** — Limits deferred tax asset recognition - No revenue recognition yet because the company has not commercialized - R&D is expensed as incurred, affecting reported losses - Government grants offset R&D and can reduce net expense - Fair value measurements affect financial instrument valuation - Equity-linked financings create dilution and share count changes - Net operating losses currently limit income tax benefit recognition --- *Last updated: 2026-04-28T20:27:11.386355+00:00*